Collegium Pharmaceutical, Inc.
COLL
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $763.2M
$23.53
▼ -0.72%
P/E
18.24
Mkt Cap
$763.2M
52-Wk Range
$23.37–$50.79
52-Week Range
$23.37 - $50.79
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 37.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary abuse-deterrent technology platform reducing misuse potential
- FDA-approved portfolio addressing unmet needs in pain management
- Regulatory expertise and established relationships with healthcare providers
- Differentiated formulations in a market increasingly focused on opioid safety
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Increasing adoption of abuse-deterrent opioids by healthcare systems and insurers
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Falling
-29.3% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying COLL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $1.92 vs $1.72 consensus (+11.6% surprise). Revenue of $199.9M vs $199.6M expected (+0.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.6%
Revenue trend · last 8Q
—
+22%
+23%
+29%
+31%
+13%
+9%
+6%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$159.3M
$181.9M
$177.8M
$188.0M
$209.4M
$205.4M
$193.5M
$199.9M
Margins · last 8Q
Gross
55.2%
Operating
1.9%
Profit
-7.5%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Mar 20, 2026
vs Industry
How COLL stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related